Eupraxia Pharmaceuticals Statistics
Total Valuation
EPRX has a market cap or net worth of $529.88 million. The enterprise value is $436.70 million.
| Market Cap | 529.88M |
| Enterprise Value | 436.70M |
Important Dates
The last earnings date was Tuesday, November 10, 2026, after market close.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EPRX has 67.24 million shares outstanding. The number of shares has increased by 67.80% in one year.
| Current Share Class | 65.91M |
| Shares Outstanding | 67.24M |
| Shares Change (YoY) | +67.80% |
| Shares Change (QoQ) | +1.92% |
| Owned by Insiders (%) | 15.53% |
| Owned by Institutions (%) | 43.27% |
| Float | 55.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.38 |
| P/TBV Ratio | 5.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.25, with a Debt / Equity ratio of 0.03.
| Current Ratio | 12.25 |
| Quick Ratio | 11.94 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -56.44% and return on invested capital (ROIC) is -38.94%.
| Return on Equity (ROE) | -56.44% |
| Return on Assets (ROA) | -36.57% |
| Return on Invested Capital (ROIC) | -38.94% |
| Return on Capital Employed (ROCE) | -53.56% |
| Weighted Average Cost of Capital (WACC) | 11.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.26M |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, EPRX has paid $48,455 in taxes.
| Income Tax | 48,455 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +29.37% in the last 52 weeks. The beta is 1.33, so EPRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | +29.37% |
| 50-Day Moving Average | 7.62 |
| 200-Day Moving Average | 7.24 |
| Relative Strength Index (RSI) | 61.06 |
| Average Volume (20 Days) | 589,386 |
Short Selling Information
The latest short interest is 6.54 million, so 9.72% of the outstanding shares have been sold short.
| Short Interest | 6.54M |
| Short Previous Month | 6.80M |
| Short % of Shares Out | 9.72% |
| Short % of Float | 11.75% |
| Short Ratio (days to cover) | 7.17 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -66.39M |
| Pretax Income | -59.07M |
| Net Income | -61.62M |
| EBITDA | -65.98M |
| EBIT | -66.39M |
| Earnings Per Share (EPS) | -$1.02 |
Balance Sheet
The company has $126.42 million in cash and $3.42 million in debt, with a net cash position of $123.00 million or $1.83 per share.
| Cash & Cash Equivalents | 126.42M |
| Total Debt | 3.42M |
| Net Cash | 123.00M |
| Net Cash Per Share | $1.83 |
| Equity (Book Value) | 121.05M |
| Book Value Per Share | 1.36 |
| Working Capital | 119.35M |
Cash Flow
In the last 12 months, operating cash flow was -$44.30 million and capital expenditures -$827,303, giving a free cash flow of -$45.12 million.
| Operating Cash Flow | -44.30M |
| Capital Expenditures | -827,303 |
| Depreciation & Amortization | 408,230 |
| Net Borrowing | n/a |
| Free Cash Flow | -45.12M |
| FCF Per Share | -$0.67 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EPRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -67.80% |
| Shareholder Yield | -67.80% |
| Earnings Yield | -12.60% |
| FCF Yield | -8.52% |
Analyst Forecast
The average price target for EPRX is $16.68, which is 106.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.68 |
| Price Target Difference | 106.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |